Introduction
Intra-articular (IA) injection of hyaluronate (HA) has been shown to be safe and effective for relieving pain in patients with osteoarthritis (OA) of the knee 1e6 and is recommended for patients who cannot be effectively managed with non-pharmacologic interventions or simple analgesics 7 . Euflexxa (BioHA) is a bioengineered 1% sodium HA that is produced by biological fermentation and does not require crosslinking 8 . It has a molecular weight range of 2.4e3.6 million daltons that is achieved by controlled fermentation, recovery, and purification processes. The safety and efficacy of a single course of BioHA was evaluated in a 26-week, randomized, double-blind, multicenter, saline-controlled FLEXX Trial 1 . The study included 588 subjects with painful knee OA who received three weekly IA injections of either BioHA or buffered saline (IA-SA). Results from the FLEXX Trial showed that IA-BioHA decreased mean pain 100 mm visual analog scale (VAS) scores immediately after a 50-foot walk test by À25.7 mm vs À18.5 mm for the IA-SA group. Both treatments were well tolerated with about 1% of subjects in each group reporting injection-site reactions.
Although many studies support the safety and efficacy of single course IA-HA injections, fewer trials have evaluated the risks and benefits of repeated series of injections. Some evidence assessing the safety and tolerability of repeat IA-HA injections exists from an open-label 12-month study of 108 subjects with knee OA, in which a second course of treatment 4e8 months after the initial intervention reduced symptoms beyond that observed after the first course of treatment 9 . Another long-term study showed repeat injections of either avian or non-avian-derived HA also improved resting pain between the first and tenth series of injections 10 .
However, 4.8% of subjects reported adverse events (AEs) (most often pain, effusion, and erythema) for avian-derived HA vs 1.7% for non-avian-derived HA between the second and tenth series of injections 10 .One recent study suggests that re-injection with HA may slow progression of structural damage in subjects with milder knee OA 11 . Thus, it is important to understand and assess both the risks and potential benefits of repeated IA-HA injections.
To further address the safety of a repeated series of IA-BioHA injections, we conducted a multicenter, 26-week, open-label Extension Study of the FLEXX Trial. Subjects completing the FLEXX Trial were offered the option to receive an additional threeinjection series (one injection per week for 3 weeks) of IA-BioHA and were followed for an additional 23 weeks after the injections during the Extension Study. This report provides new information about the safety and efficacy of re-injection of IA-BioHA in subjects who received IA-BioHA in the FLEXX Trial as well as the effects of a single series of IA-BioHA injections in the 26-week Extension Study for subjects who received IA-SA in the FLEXX Trial.
Subjects and methods

Summary of the FLEXX Trial
The FLEXX Trial 1 was a randomized (1:1), double-blind, multicenter, saline-controlled study that enrolled subjects with OA of the knee according to American College of Rheumatology criteria: moderate-to-severe joint pain (a score of 41e90 on a 100 mm VAS) immediately following a 50-foot walk, and a bilateral standing anterior-posterior radiograph demonstrating Kellgren and Lawrence grade 2 or 3 OA of the target knee. Five hundred eighty-eight (588) subjects were randomized to either IA-BioHA (n ¼ 293) or IA-SA (n ¼ 295). Two hundred fifty-seven subjects (88%) who received IA-BioHA and 259 subjects who received IA-SA (88%), a total of 516 subjects, completed the FLEXX Trial (Fig. 1) . The primary efficacy endpoint of the FLEXX Trial was the difference between IA-BioHA and IA-SA in subjects' pain scores, measured on a 100-mm VAS after a 50-foot walk test and compared to baseline at 26 weeks following treatment. Safety was assessed by monitoring and reporting vital signs, physical examination of the target knee following injection, AEs, and concomitant medications. The sample size for the FLEXX Trial was based on the requirement for 90% power to detect an 8.0 mm difference between average IABioHA and IA-SA scores at the two-sided 5% significance level and an estimated 30% dropout rate by week 26 1 .
Study design for the FLEXX Trial Extension Study
The Extension Study was a multicenter open-label 26-week trial. All 516 subjects who completed the FLEXX Trial were eligible for the Extension Study and remained without knowledge of whether they received IA-BioHA or IA-SA in the initial series of injections (Fig. 1) .
The FLEXX Trial Extension Study was conducted in accordance with the ethical principles that have their origins in the Declaration of Helsinki and in compliance with the approved protocol, Good Clinical Practice, and applicable regulatory requirements. Consent was obtained for participation in the Extension Study from each subject in accordance with local Institutional Review Board oversight.
Treatment
IA-BioHA is a 20 mg per 2 mL viscoelastic sterile solution of highly purified, non-cross-linked, high molecular weight (2.4e3.6 million daltons) hyaluronan extracted from bacterial cells in phosphate-buffered saline. All subjects enrolled in the Extension Study received one 2 mL injection of IA-BioHA per week for 3 weeks in the same knee targeted during the FLEXX Trial. Skilled injectors were instructed to cleanse the skin around the injection site with betadine or alcohol before administering lidocaine 1% (without epinephrine) into the skin and subcutaneous tissue. IA-BioHA was injected by either a supra-or infra-patellar approach without fluoroscopic or ultrasound guidance. If aspiration of the joint was necessary, the joint capsule could be infiltrated with lidocaine using a 20-to 23-gauge needle. However, if an effusion was present, IA-BioHA was injected using a 16-to 18-gauge needle. Injections were administered at baseline (week 26) and weeks 27 and 28. Subjects were interviewed by telephone at week 34 or 35 and office visits were carried out at weeks 41 and 52 (all time points refer to the time from initiation of the FLEXX Trial). 
Safety
All AEs were recorded at each visit/interview. Safety variables also included laboratory parameters, vital signs, and physical examination of the knee.
Statistical methods
Efficacy variables were analyzed using an intent-to-treat (ITT) approach. The population for efficacy analysis included subjects who had an evaluation at baseline of the Extension Study (week 26), received at least one injection of IA-BioHA, and had at least one post-baseline evaluation during the Extension Study. Safety analyses included all 433 subjects enrolled in the Extension Study.
Differences in baseline characteristics between the 219 subjects treated with IA-BioHA and the 214 subjects treated with IA-SA during the FLEXX Trial were assessed with Chi-square tests for categorical variables and Student's 2-sample t-tests for continuous variables, with or without Satterthwaite's correction for unequal variances, as appropriate.
Data summaries for evaluation of safety in the Extension Study included the overall number and percentage of subjects experiencing at least one treatment-emergent AE (TEAE) and listing of AEs that occurred with a prevalence of >1% in the Extension Study. Percentages of patients experiencing TEAEs during the doubleblind trial are also included for comparison. Ninety-five percent confidence intervals (CIs) for all TEAE percentages were calculated using the (second-order correct) Wilson interval.
For evaluation of efficacy, average changes from baseline in pain VAS scores were estimated with least squares means (LSM) AE standard error of the mean (SEM), derived with a repeatedmeasures, mixed-effects analysis of covariance (ANCOVA) model, with no data imputation for each time point. The structure of the correlation pattern of patients repeated VAS scores of changes from baseline is user specified. That which passed goodness-of-fit criteria resulted in using an exchangeable correlation structure (compound symmetry) for the repeated measurements. The model included the following factors: baseline pain score on the 50-foot walk test, trial center, core treatment group, trial week, and treatment group-bytrial week interaction. The trial center was classified as a random factor and trial week as a repeated measure. The interactions between study center and treatment group and between the covariate and treatment group were also to be included in the model if they were significant, but this was not the case for either interaction.
The other efficacy outcomes of OARSIeOMERACT responder rates, the three WOMAC domains of Pain, Stiffness, and Disability, Patient's Global Assessment, the average number of study-specific acetaminophen (rescue medication) tablets consumed per week, and SF-36 Health Survey average scores for Physical Functioning (PF) and Bodily Pain (BP) were summarized with descriptive statistics as changes from baseline during the Extension Study (between week 26 and week 52) and percentage changes from the FLEXX Trial baseline (week 0). Prior to analysis, all SF-36 items were transformed into norm-based values using data from the 1988 United States general population.
Results
Subjects
Three hundred seventy-eight (378) subjects (87%) completed the Extension Study, including 187 subjects treated with IA-SA and 191 treated with IA-BioHA in the FLEXX Trial (Fig. 1) . Eleven subjects who did not receive all three injections were included in the group of discontinuations [study-related AEs (two), unrelated AEs (three), withdrew consent (two), lost to follow-up (four)]. Eight subjects failed to meet criteria for inclusion in the ITT efficacy analysis and the population evaluated for efficacy thus included 425 subjects. Two of the 425 subjects in the efficacy analysis received only two injections and nine subjects received only one injection during the Extension Study.
There were no differences in the demographics of the subjects treated with IA-SA or IA-BioHA during the FLEXX Trial who agreed to continue in the 26-week Extension Study (Tables I and II) .
Safety
Overall, 43.4% of subjects reported at least one TEAE during the Extension Study compared to 55.4% who reported at least one TEAE during the double-blind FLEXX Trial (Table III) . The percentages of subjects experiencing at least one AE in the Extension Study were similar for those who previously received IA-BioHA (43.8%) or IA-SA (43.0%) during the FLEXX Trial. The AEs that occurred most often in the Extension Study were arthralgia (9.9%), injury (4.4%), nasopharyngitis (3.5%), upper respiratory infections (3%), and joint swelling in the soft tissue at the injection site (2.3%) (Table III) . There were no differences in the AE profiles for subjects receiving IA-SA as their initial injection during the FLEXX Trial or IA-BioHA re-injection during the Extension Study (Table III) .
Among subjects with at least one AE in the Extension Study, 21 (4.8%) had an event considered related to the IA-BioHA. The most frequent treatment-related AEs were arthralgia (2.8%), joint swelling (1.2%), peripheral edema (0.7%), and injection site pain (0.5%). There was no detectable pre-treatment or post-treatment synovitis or synovial effusions in either the FLEXX Trial or the Extension Study. Twenty events classified as serious TEAEs were reported in 12 subjects (2.8%) during the Extension Study; none were considered related to study treatment. There were no deaths. Two subjects re-injected with IA-BioHA had treatment-related AEs of joint pain that led to discontinuation from the Extension Study.
Efficacy
Pain VAS At the end of the FLEXX Trial, there was a À26.5 mm reduction in pain VAS scores for subjects treated with IA-BioHA and a À21.5 mm pain reduction in those who received IA-SA (Fig. 2) . Subjects treated with BioHA in the FLEXX Trial who continued into the Extension Study had a further À3.5 mm decrease in the pain scale scores between weeks 26 and 52. Those treated with IA-SA in the FLEXX Trial had a further À9.0 mm decrease in pain scale scores between weeks 26 and 52 during the Extension Study (Fig. 2) . For both groups, improvement occurred by week 27 and was sustained to week 52.
OMERACTeOARSI responder rate
Among the 425 subjects analyzed for efficacy during the Extension Study, the OMERACTeOARSI responder rate during the FLEXX Trial (from week 0 to week 26) was 67% for the subjects who received IA-BioHA and 59% for those treated with IA-SA. The responder rate for all subjects was 75.3% at the completion of the Extension Study (week 52) (Table IV) .
WOMAC pain, stiffness, and disability
Between the end of the FLEXX Trial and the end of the Extension Study, the mean WOMAC Pain score decreased an additional À6.1 mm, WOMAC Stiffness decreased an additional À5.9 mm, and WOMAC Disability decreased an additional À5.6 mm. Overall WOMAC Pain, Stiffness, and Disability scores decreased by 47.2%, 42.5%, and 44.1%, respectively, from the FLEXX Trial baseline to the end of the Extension Study (Table IV) . N ¼ number of subjects in the safety population; n ¼ number of subjects having experienced the TEAE within the organ system class; (%) ¼ percentage of subjects ¼ (n/N) 100. AEs categorized by the treatment arm for the double-blind trial. 
Patient's Global Assessment
Patient's Global Assessment improved an additional À8.1 mm, an overall 51.6% decrease from initiation of the FLEXX Trial to the end of the Extension Study.
Use of rescue medication
Mean acetaminophen use was reduced from 14.6 to 12.8 tablets per week over the course of the FLEXX Trial. At the end of the Extension Study, acetaminophen use was further reduced to 9.5 tablets per week, representing an overall 34.9% reduction from the beginning of the FLEXX Trial (Table IV) .
SF-36
At FLEXX Trial baseline, the mean SF-36 PF and BP scale scores were 32.7 and 36.9, respectively. At the end of the FLEXX Trial, these scores improved to 36.7 and 40.4. At the end of the Extension Study, the scores for the PF and BP scales were 37.7 and 42.7. The mean changes from the end of the FLEXX Trial to the end of the Extension Study were 0.9 and 2.2 for SF-36 PF and BP, respectively. From FLEXX Trial baseline to the end of the Extension Study, there were 15.2% and 15.7% improvements for SF-36 PF and BP, respectively.
Discussion
Although efficacy of IA-HA injections has been established previously, safety of repeated HA injections, including BioHA, is understudied. The FLEXX Trial Extension Study showed that a repeated series of three weekly injections of IA-BioHA given 23 weeks after an initial three-injection treatment course was effective, safe, and well tolerated in subjects with chronic painful OA of the knee. Pain reduction observed from an initial injection of IABioHA during the FLEXX Trial was sustained for an additional 23 weeks during the Extension Study after IA-BioHA re-injection. No subject reported a joint effusion during either the initial FLEXX Trial or following re-injection of IA-BioHA during the Extension Study.
The positive results obtained with re-injection of IA-BioHA in the present study are consistent with those from prior trials that have addressed this issue. An observational study of 108 subjects with knee OA showed decreased pain in four subjects who received a repeat series of five injections of HA 9 . Another study of 306 subjects with knee OA who received four series of five HA injections every 6 months indicated that HA was significantly superior to saline with respect to achievement of OARSI responder criteria over 3.5 years of follow-up 14 . A third study, which included 897 subjects with knee OA who received two series of a 500,000e730,000 dalton non-avian-derived HA, showed that improvements in walking and resting pain following the second series of injections were at least equivalent to those after the first series 15 . Safety results and AEs associated with HA re-injection were not reported in these studies.
Some data regarding safety of repeated HA injections have been reported previously. Results of one small-scale study of 39 subjects with knee OA who received a series of three injections with either saline or HA every 3 months over 1 year indicated that HA reinjection was not significantly superior to placebo for improving pain or function. In this trial, 40% of the 20 HA-treated subjects reported pain during or immediately after the injection for at least one of the nine injections for a total of 17 events 16 . A trial of 75 subjects with knee OA treated with a three-injection series of a straight chain avian-derived HA every 6 months for 30 months showed that pain decreased following the first injection and continued to decline throughout the study. Neither local nor systemic AEs were observed with re-injection; however, five subjects (6.6%) complained of localized pain after IA injection 17 . Several published studies report differences in AE risk associated with hylan and different HA preparations. A systematic review and meta-analysis of thirteen randomized, controlled clinical trials with a pooled total of 2085 patients revealed an increased risk associated with hylan for any local AE (relative risk [RR] 1.91; 95% CI 1.04, 3.49; I ¼ 28%) and for flares (RR 2.04; 95% CI 1.18, 3.53; I ¼ 0%), however there was no difference observed in efficacy for hylan and HAs 18 .
One multicenter, subject-blinded, randomized control trial included 660 subjects with symptomatic knee OA who were randomized to three IA injections of either a high molecular weight (average molecular weight 6 million daltons) avian-derived, crosslinked hylan or one of two HA preparations; a non-cross-linked medium molecular weight (1.0e2.9 million daltons) avian-derived HA or a non-cross-linked low molecular weight (about 1.5 million daltons) HA obtained through bacterial fermentation. Subjects completing the initial phase of the trial were offered an additional three-injection series during months 7e12 of the study. Although pain relief was similar in all treatment groups, re-injection of the high molecular weight, cross-linked, avian-derived hylan was associated with more local AEs (9.1%), effusions (7.3%), and flares (6.4%) than the HA preparations (2.7%, 2.7%, and 0%, respectively) 2 .
Repeated injections of avian and non-avian-derived HA were also compared in a non-randomized study that included 4412 subjects treated over the period from 1997 to 2007. The HA preparation used was based on subject preference and subsequent series of injections were at the subjects' discretion. Study results indicated that both the avian and non-avian preparations improved resting pain over as many as 10 series of injections. AEs were reported for 4.8% of subjects receiving avian-derived HA vs 1.7% for those treated with the non-avian preparation 10 .
Although the FLEXX Trial Extension Study provided new information about the safety and efficacy of BioHA re-injection, the trial had limitations that should be acknowledged. The Extension Study was an open-label trial and lacked a control group. This aspect of the study design may have influenced subjects' perceptions and reporting of efficacy, but it was necessary to maintain subject participation, as it is very difficult to enroll subjects in a long-term study if they are not guaranteed active therapy. The open-label design of the Extension Study was unlikely to have influenced AE reporting, especially since the subjects remained blinded to previous therapy, and subjects from both the IA-SA and IA-BioHA treated groups reported similar numbers of AEs. A second limitation of the Extension Study was that it included only a single course of retreatment. Thus, it is not known whether further series of reinjections would result in different efficacy or safety findings. Finally, while the sample size for this trial was large relative to several of the other long-term evaluations of repeated injections of IA-HA, conclusions regarding safety must be tempered. With sample sizes of 200, 300, and 400, for example, there is 95% chance of observing at least one event with rates of 1.5%, 1% and 0.75%, respectively. Detection of very rare AEs would require study of many thousands of subjects 19 .
In conclusion, results from this FLEXX Trial Extension Study showed that re-injection with BioHA was safe and effective. Comparison of Extension Study results with those from prior trials suggests further that the efficacy of IA-BioHA re-injection was at least equivalent to that reported for re-injection of other IA-HA agents, and that the AE profile for re-injection of IA-BioHA was at least equal, if not superior, to that reported for other IA-HA preparations. Results from subjects who received their initial treatment with IA-BioHA in the FLEXX Trail Extension Study also supported the efficacy and safety of this preparation.
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